HIV

Stability of exhausted T cells in mice effects the durability of reinvigoration by PD-1 blockade.

Highly active antiretroviral therapy (HAART) prolongs survival for patients with HIV, but increases the risk for other chronic diseases.

Much research and literature has been devoted to cardiovascular diseases, neurocognitive diseases, and neuroendocrine dysfunction in the aging patient with HIV, but cancer in patients with HIV is also a growing concern.

The 14th Report on Carcinogens added 5 viruses and 2 substances to the list of known carcinogens.

African Americans have the most severe burden of HIV in the United States.

Researchers have identified an antibody that can neutralize 98% of HIV strains, and may serve as a potential candidate for future HIV treatment and prevention.

Potent antibody may prove more advantageous for HIV prevention and treatment strategies.

Viral loads were reduced in SIV-infected rhesus monkeys given an experimental vaccine in combination with an immune stimulant.

Broadly neutralizing antibody delays viral rebound and opens doors for future HIV vaccines.

Gilenya may cause an increase in CD56+-expressing T cells, which can cause MS relapse.

Researchers develop a USB device that can detect HIV with 95% accuracy.

Virologically suppressed HIV-positive patients benefit from switching their treatment regimens to those involving Odefsey.

Beneficial results seen when switching to a HIV regimen including Odefsey.

Findings may provide further knowledge of how patients end up developing HIV-1 associated nephropathy.

With the many agents available for highly active antiretroviral therapy (HAART), selecting the best regimen in HAART-naïve patients is not an easy task.

HIV positive patients coinfected with hepatitis may face elevated cancer risk.

A cell-editing platform allowed researchers to find genetic mutations that allow human immune cells to be resistant to HIV.

Descovy showed non-inferiority to Truvada, and benefited bone and kidney health.

Ibalizumab for multi-drug resistant HIV showed significant promise fighting the disease.

HIV has been an epidemic for 30 years. Initially, the health system relied on behavioral interventions to slow the spread of the virus.

Ibalizumab achieves primary endpoint in decreasing the viral load of patients with drug-resistant HIV.

Ibalizumab caused 83% of HIV-positive patients to achieve a virologic response.

An automated algorithm was able to select HIV-positive individuals who would benefit the most from PrEP.

Dolutegravir/abacavir shows a solid safety profile and a high barrier to resistance.

Researchers seek to improve HIV drug therapies through nanomedicine.